Because AT1 receptor levels are increased in diabetic cardiomyopathy [51], interruption of this vicious circle of SCD-induced AT1 receptor up-regulation by an AT1 receptor blocker is expected to be most efficacious in diabetic patients with heart failure. The gene discussed is AGTR1; the disease is Schnyder corneal dystrophy.